What is it about?
In this study, we sought to determine the incidence and potential risk factors of pneumothorax in critically ill adults with COVID-19. The incidence of pneumothorax was 10% and associated with higher mortality. Strikingly, receipt of tocilizumab was associated with an increased risk of developing pneumothorax.
Featured Image
Photo by CDC on Unsplash
Why is it important?
This is the first study to find that the administration of tocilizumab significantly increased the risk of developing pneumothorax.
Read the Original
This page is a summary of: Incidence and risk factors of COVID-19 associated pneumothorax, PLoS ONE, August 2022, PLOS,
DOI: 10.1371/journal.pone.0271964.
You can read the full text:
Contributors
The following have contributed to this page
